跳到主要内容
Learn Motion
探索课程产品能力价格

下载 Learn Motion

用手机扫描二维码,下载 App。

App Store

扫码从 App Store 下载 Learn Motion打开商店页面

Google Play

扫码从 Google Play 下载 Learn Motion打开商店页面
登录
Learn Motion

How AI Is Changing Cancer Drug Discovery

1Why Cancer Drug Discovery Is So Hard2What AI Can and Cannot Do Here3Finding the Right Target4Designing Molecules with AI5Testing, Trials, and Real-World Impact6What's Next and What to Watch
Finding the Right Target

One Real Case: A Protein Nobody Was Looking At

3 / 3
Take the example apart. The researchers did not hand the machine a disease and ask for a cure. They built a map of relationships already published in the literature, then asked a narrower question: which proteins are connected to this disease but have not been pursued? The system returned a candidate, and here is the part that matters — the team did not stop there. They ran experiments. The AI produced a suggestion; the lab produced the evidence. That division of labor is the whole point. Now look at the caution underneath. We read about the cases where the suggestion held up. The cases where it did not are rarely published, so the record we see is friendlier than reality. And remember what is at stake: once a target is chosen, years of work are built on it, and that work cannot be recovered if the target is wrong.
0:00 / 0:00

A knowledge graph proposes a target

Researchers built a knowledge graph from published literature and databases, asked which proteins were linked to the disease but under-explored, and got RIPK1 back as a candidate. Laboratory experiments then tested whether blocking RIPK1 changed disease biology. The AI's role was to assemble scattered evidence into a ranked suggestion; the experiments decided whether the suggestion held.

What the case demonstrates

The value is breadth and ordering, not proof. A model can weigh thousands of weak connections at once and surface a candidate that is not the field's current favorite. But the ranking is a hypothesis: the target only becomes credible when an experiment confirms that changing it changes the disease. Published cases also over-represent successes, so the visible record of AI-informed targets is more favorable than the true hit rate.

Why this decision is hard to undo

Once a target is chosen, years of chemistry and testing are built on top of it. If the target turns out to be wrong, that work is not recoverable — which is why a ranked list is treated as a starting point for experiments, not as a decision.

参考资料

  1. [1]BenevolentAI — RIPK1 inhibitor for ALSbenevolent.com
上一页3 / 3下一页

Learn Motion

生成课程,认真学会。

运营方:Wuhan Daoyin Technology Co., Ltd.

联系我们: [email protected]
隐私政策用户服务协议

© 2026 Learn Motion